*Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA; †Department of Oncology, University of Torino, Italy; and ‡Département de Radiothérapie, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
J Thorac Oncol. 2014 Oct;9(10):1426-33. doi: 10.1097/JTO.0000000000000317.
An increasing body of experience suggests that oligometastasis represents a minimal metastatic state with the potential for cure or prolonged survival in selected patients treated with radical local therapy to all identified sites of disease. The main clinical scenarios managed by thoracic oncology specialists are pulmonary oligometastases from primary malignancies of other anatomic sites and primary lung cancer with oligometastases to lung or other organs. Surgery has been a mainstay of treatment in these situations, with remarkably favorable outcomes following pulmonary metastasectomy in well-selected patient cohorts. As with early stage lung cancer in patients who are medically inoperable, stereotactic ablative radiotherapy is emerging as a prominent local treatment option for oligometastatic disease. We review the role and clinical experience of stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.
越来越多的经验表明,寡转移代表了一种微小的转移状态,对于接受根治性局部治疗的选定患者,所有已识别的疾病部位都有治愈或延长生存的潜力。胸肿瘤学专家管理的主要临床情况是来自其他解剖部位原发性恶性肿瘤的肺寡转移和肺或其他器官的寡转移原发性肺癌。在这些情况下,手术一直是治疗的主要方法,在精心挑选的患者队列中,肺转移切除术的结果非常理想。与不能手术的早期肺癌患者一样,立体定向消融放疗作为寡转移性疾病的一种突出的局部治疗选择正在出现。我们回顾了立体定向消融放疗在肺寡转移和寡转移性肺癌中的作用和临床经验。